Clinical research - Press Releases

Date	Title	Company
20-Dec-2023	Dr. Vince Clinical Research Launches New Solution for Organ Impairment Studies	Dr. Vince Clinical Research
19-Dec-2023	Combination Therapy for Colorectal Cancer Shows Benefit Despite RAS Gene Mutations	Karl Landsteiner University of Health Sciences
18-Dec-2023	Vicore Appoints Leading Respiratory Medicine Developer Dr. Bertil Lindmark MD, PhD, as Chief Medical Officer	Vicore Pharma Holding AB
18-Dec-2023	Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies	Achilles Therapeutics plc
14-Dec-2023	CSL Behring’s HEMGENIX® Granted First-Ever Direct Access in France for Haemophilia B Gene Therapy	CSL Behring
14-Dec-2023	Advanced Therapies Week Announces Move to San Diego for 2025, Ushering in a New Era of Celebrating Progress and Innovation in the Industry	Phacilitate
14-Dec-2023	Vandria Announces $20.6M (CHF18M) Series A Financing Led by ND Capital to Drive CNS Clinical Program and Mitochondrial Therapeutics Platform	Vandria
14-Dec-2023	Lindus Health and Thirty Madison complete enrolment of personalised dermatology care pilot study	Lindus Health
14-Dec-2023	Nottingham CRO Platelet Services marks fifth anniversary	Platelet Services
14-Dec-2023	Biocomposites exceeds revenue expectations and takes a big step forward in its research and development	Biocomposites
14-Dec-2023	DARZALEX® (daratumumab) Subcutaneous Formulation-Based Quadruplet Therapy Regimen Shows Significant Improvement in Outcomes for Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma	Janssen
14-Dec-2023	CellCentric discloses significant new clinical data, demonstrating inobrodib’s efficacy in ongoing Phase I/IIa clinical trials	CellCentric
14-Dec-2023	Blueprint Medicines’ AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis	Blueprint Medicines’ AYVAKYT® (avapritinib)
14-Dec-2023	Modus Therapeutics presented data on sevuparin demonstrating its potential to treat anemia in chronic kidney disease at the annual American Society of Hematology (ASH)	Modus
14-Dec-2023	Families affected by ALS urged to join free program to uncover their genetic risk, contribute to research, and access new therapies	• Sano Genetics
14-Dec-2023	POLB 001 Data Presented at ASH	Poolbeg Pharma plc
14-Dec-2023	1ST Biotherapeutics, Inc. Announces First Patient Dosed in Phase I/II Study of HPK1 Inhibitor FB849 in Patients with Advanced Solid Tumors	1ST Biotherapeutics
12-Dec-2023	NEW ANALYSES PRESENTED AT ASH 2023 SUPPORT THE POTENTIAL LONG-TERM RESPONSE AND SAFETY OF KITE’S TECARTUS® (BREXUCABTAGENE AUTOLEUCEL) IN PATIENTS WITH AGGRESSIVE BLOOD CANCERS	KITE
12-Dec-2023	Scottish Medicines Consortium Accepts Libtayo®▼ (cemiplimab) as First Approved Drug Treatment for Advanced Cutaneous Squamous Cell Carcinoma in Scotland	Libtayo®▼
11-Dec-2023	POLB 001 – targeting Cytokine Release Syndrome (CRS) associated with cancer immunotherapies	Poolbeg Pharma plc